Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission

NCT06021197 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT06021197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06021197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission
Lead sponsor
China Medical University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 12, 2023
Completion date
March 31, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia